{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:40:26Z","timestamp":1791333626587,"version":"4.3.1"},"reference-count":115,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T00:00:00Z","timestamp":1691798400000},"content-version":"vor","delay-in-days":5336,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1016\/j.nurt.2008.10.035","type":"journal-article","created":{"date-parts":[[2008,12,25]],"date-time":"2008-12-25T05:41:37Z","timestamp":1230183697000},"page":"141-151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"title":["Dual-Target\u2013Directed Drugs that Block Monoamine Oxidase B and Adenosine A  Receptors for Parkinson's Disease"],"prefix":"10.1016","volume":"6","author":[{"given":"Jacobus P.","family":"Petzer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Neal","family":"Castagnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Schwarzschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang-Fan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis J.","family":"Van der Schyf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nurt.2008.10.035_bib1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.pneurobio.2007.10.003","article-title":"Disease-modifying drugs and Parkinson's disease","volume":"84","author":"Allain","year":"2008","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.nurt.2008.10.035_bib2","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0896-6273(03)00568-3","article-title":"Parkinson's disease: mechanisms and models","volume":"39","author":"Dauer","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/j.nurt.2008.10.035_bib3","doi-asserted-by":"crossref","first-page":"155S","DOI":"10.1592\/phco.27.12part2.155S","article-title":"Overview of Parkinson's disease","volume":"27","author":"Lew","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.nurt.2008.10.035_bib4","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s11910-008-0047-5","article-title":"Neuroprotection in Parkinson's disease: myth or reality?","volume":"8","author":"Voss","year":"2008","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.nurt.2008.10.035_bib5","doi-asserted-by":"crossref","first-page":"161S","DOI":"10.1592\/phco.27.12part2.161S","article-title":"Pharmacotherapy for Parkinson's disease","volume":"27","author":"Chen","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.nurt.2008.10.035_bib6","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2165\/00023210-200721080-00005","article-title":"Medical management of levodopa-associated motor complications in patients with Parkinson's disease","volume":"21","author":"Jankovic","year":"2007","journal-title":"CNS Drugs"},{"key":"10.1016\/j.nurt.2008.10.035_bib7","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.disamonth.2007.05.002","article-title":"Current pharmacotherapeutic treatment options in Parkinson's disease","volume":"53","author":"Rezak","year":"2007","journal-title":"Dis Mon"},{"key":"10.1016\/j.nurt.2008.10.035_bib8","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2165\/00002512-200522090-00002","article-title":"Alternatives to levodopa in the initial treatment of early Parkinson's disease","volume":"22","author":"Lees","year":"2005","journal-title":"Drugs Aging"},{"key":"10.1016\/j.nurt.2008.10.035_bib9","doi-asserted-by":"crossref","first-page":"174S","DOI":"10.1592\/phco.27.12part2.174S","article-title":"Monoamine oxidase-B inhibition in the treatment of Parkinson's disease","volume":"27","author":"Fernandez","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.nurt.2008.10.035_bib10","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/236225b0","article-title":"Human brain monoamine oxidase: multiple forms and selective inhibitors","volume":"236","author":"Youdim","year":"1972","journal-title":"Nature"},{"key":"10.1016\/j.nurt.2008.10.035_bib11","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/225817a0","article-title":"Multiple forms of human brain mitochondrial monoamine oxidase","volume":"225","author":"Collins","year":"1970","journal-title":"Nature"},{"key":"10.1016\/j.nurt.2008.10.035_bib12","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0006-8993(96)00761-5","article-title":"Monoamine oxidase-dependent metabolism of dopamine in the striatum and substantia nigra of L-DOPA-treated monkeys","volume":"738","author":"Di Monte","year":"1996","journal-title":"Brain Res"},{"key":"10.1016\/j.nurt.2008.10.035_bib13","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/978-3-7091-6499-0_28","article-title":"Increased striatal dopamine production from L-DOPA following selective inhibition of monoamine oxidase B by R(+)-N-propargyl-1-aminoindan (rasagiline) in the monkey","volume":"52","author":"Finberg","year":"1998","journal-title":"J Neural Transm Suppl"},{"key":"10.1016\/j.nurt.2008.10.035_bib14","doi-asserted-by":"crossref","first-page":"S287","DOI":"10.1038\/sj.bjp.0706464","article-title":"Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness","volume":"147","author":"Youdim","year":"2006","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.nurt.2008.10.035_bib15","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0161-813X(03)00095-0","article-title":"Monoamine oxidase expression during development and aging","volume":"25","author":"Nicotra","year":"2004","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.nurt.2008.10.035_bib16","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0197-4580(97)00037-7","article-title":"Age-related increases in brain monoamine oxidase B in living healthy human subjects","volume":"18","author":"Fowler","year":"1997","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.nurt.2008.10.035_bib17","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.brainres.2005.02.043","article-title":"Effects of depression, cigarette smoking, and age on monoamine oxidase B in amygdaloid nuclei","volume":"1043","author":"Karolewicz","year":"2005","journal-title":"Brain Res"},{"key":"10.1016\/j.nurt.2008.10.035_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF01249185","article-title":"The effect of age on the activity and molecular properties of human brain monoamine oxidase","volume":"49","author":"Fowler","year":"1980","journal-title":"J Neural Transm"},{"key":"10.1016\/j.nurt.2008.10.035_bib19","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.pharmthera.2004.10.007","article-title":"Therapeutic potential of adenosine A2A receptor antagonists in Parkinson's disease","volume":"105","author":"Xu","year":"2005","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.nurt.2008.10.035_bib20","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1016\/j.lfs.2005.04.029","article-title":"New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists","volume":"77","author":"Pinna","year":"2005","journal-title":"Life Sci"},{"key":"10.1016\/j.nurt.2008.10.035_bib21","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.pneurobio.2007.07.001","article-title":"Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications","volume":"83","author":"Morelli","year":"2007","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.nurt.2008.10.035_bib22","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.tins.2006.09.004","article-title":"Targeting adenosine A2A receptors in Parkinson's disease","volume":"29","author":"Schwarzschild","year":"2006","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.nurt.2008.10.035_bib23","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0014-4886(03)00250-4","article-title":"A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease","volume":"184","author":"Bibbiani","year":"2003","journal-title":"Exp Neurol"},{"key":"10.1016\/j.nurt.2008.10.035_bib24","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1021\/jm00062a005","article-title":"Structure-activity relationships of 8-styrylxanthines as A2-selective adenosine antagonists","volume":"36","author":"Jacobson","year":"1993","journal-title":"J Med Chem"},{"key":"10.1016\/j.nurt.2008.10.035_bib25","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1021\/jm970515+","article-title":"Synthesis and structure-activity relationships of 3,7-dimethyl-1-propargylxanthine derivatives, A2A-selective adenosine receptor antagonists","volume":"40","author":"M\u00fcller","year":"1997","journal-title":"J Med Chem"},{"key":"10.1016\/j.nurt.2008.10.035_bib26","doi-asserted-by":"crossref","first-page":"36040","DOI":"10.1074\/jbc.M206830200","article-title":"8-(3-Chlorostyryl) caffeine may attenuate MPTP neurotoxicity through dual actions of monoamine oxidase inhibition and A2A receptor antagonism","volume":"277","author":"Chen","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.nurt.2008.10.035_bib27","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S0968-0896(02)00648-X","article-title":"Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists","volume":"11","author":"Petzer","year":"2003","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.nurt.2008.10.035_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2006.01.011","article-title":"Inhibition of monoamine oxidase B by analogues of the adenosine A2A receptor antagonist (E)-8-(3-chlorostyryl) caffeine (CSC)","volume":"14","author":"Vlok","year":"2006","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.nurt.2008.10.035_bib29","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0031-6997(24)01511-4","article-title":"International Union of Pharmacology","volume":"53","author":"Fredholm","year":"2001","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.nurt.2008.10.035_bib30","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/syn.20099","article-title":"First visualization of adenosine A2A receptors in the human brain by positron emission tomography with [11C]TMSX","volume":"55","author":"Ishiwata","year":"2005","journal-title":"Synapse"},{"key":"10.1016\/j.nurt.2008.10.035_bib31","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0014-2999(89)90571-2","article-title":"Direct autoradiographic localization of adenosine A2 receptors in the rat brain using the A2-selective agonist, [3H]CGS 21680","volume":"168","author":"Jarvis","year":"1989","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.nurt.2008.10.035_bib32","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/j.1471-4159.1991.tb08257.x","article-title":"Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study","volume":"57","author":"Schiffmann","year":"1991","journal-title":"J Neurochem"},{"key":"10.1016\/j.nurt.2008.10.035_bib33","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/0169-328X(92)90173-9","article-title":"Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum","volume":"14","author":"Fink","year":"1992","journal-title":"Brain Res Mol Brain Res"},{"key":"10.1016\/j.nurt.2008.10.035_bib34","doi-asserted-by":"crossref","first-page":"7238","DOI":"10.1073\/pnas.88.16.7238","article-title":"Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes","volume":"88","author":"Ferr\u00e9","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.nurt.2008.10.035_bib35","doi-asserted-by":"crossref","first-page":"5402","DOI":"10.1523\/JNEUROSCI.13-12-05402.1993","article-title":"The striopallidal neuron: a main locus for adenosine-dopamine interactions in the brain","volume":"13","author":"Ferr\u00e9","year":"1993","journal-title":"J Neurosci"},{"key":"10.1016\/j.nurt.2008.10.035_bib36","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S0166-2236(97)01096-5","article-title":"Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia","volume":"20","author":"Ferr\u00e9","year":"1997","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.nurt.2008.10.035_bib37","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/ana.410430415","article-title":"Adenosine A2A antagonist: a novel anti-Parkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys","volume":"43","author":"Kanda","year":"1998","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nurt.2008.10.035_bib38","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1073\/pnas.98.4.1970","article-title":"The role of the D2 dopamine receptor (D2R) in A2A adenosine receptor (A2AR)-mediated behavioral and cellular responses as revealed by A2A and D2 receptor knockout mice","volume":"98","author":"Chen","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.nurt.2008.10.035_bib39","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1046\/j.1471-4159.2003.01632.x","article-title":"Cellular and behavioural effects of the adenosine A2A receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia","volume":"84","author":"Lundblad","year":"2003","journal-title":"J Neurochem"},{"key":"10.1016\/j.nurt.2008.10.035_bib40","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0014-2999(96)00944-2","article-title":"Adenosine A2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats","volume":"321","author":"Fenu","year":"1997","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.nurt.2008.10.035_bib41","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/0006-8993(93)90925-D","article-title":"Adenosine receptor antagonists potentiate dopamine receptor agonist-induced rotational behavior in 6-hydroxydopamine-lesioned rats","volume":"613","author":"Jiang","year":"1993","journal-title":"Brain Res"},{"key":"10.1016\/j.nurt.2008.10.035_bib42","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1212\/WNL.52.8.1673","article-title":"Anti-Parkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys","volume":"52","author":"Grondin","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.10.035_bib43","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1006\/exnr.2000.7350","article-title":"Combined use of the adenosine A2A antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases anti-Parkinsonian activity but not dyskinesia in MPTP-treated monkeys","volume":"162","author":"Kanda","year":"2000","journal-title":"Exp Neurol"},{"key":"10.1016\/j.nurt.2008.10.035_bib44","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejphar.2006.07.017","article-title":"The novel adenosine A2A receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets","volume":"546","author":"Rose","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.nurt.2008.10.035_bib45","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0304-3940(98)00533-3","article-title":"Adenosine A1 and A2A receptor antagonists stimulate motor activity: evidence for an increased effectiveness in aged rats","volume":"251","author":"Popoli","year":"1998","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.nurt.2008.10.035_bib46","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1016\/S0960-894X(97)00440-X","article-title":"Adenosine A2A antagonists with potent anti-cataleptic activity","volume":"18","author":"Shimada","year":"1997","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.nurt.2008.10.035_bib47","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1212\/01.WNL.0000073136.00548.D4","article-title":"Adenosine A2A receptor antagonist treatment of Parkinson's disease","volume":"61","author":"Bara-Jimenez","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.10.035_bib48","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1212\/01.WNL.0000081227.84197.0B","article-title":"Randomized trial of the adenosine A2A receptor antagonist istradefylline in advanced PD","volume":"61","author":"Hauser","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.10.035_bib49","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1212\/01.WNL.0000095223.08711.48","article-title":"Translating A2A antagonist KW6002 from animal models to parkinsonian patients","volume":"61","author":"Chase","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.10.035_bib50","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ana.21315","article-title":"Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces \u201coff\u201d time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005)","volume":"63","author":"LeWitt","year":"2008","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nurt.2008.10.035_bib51","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0301-0082(98)00053-7","article-title":"Tremulous jaw movements in rats: a model of parkinsonian tremor","volume":"56","author":"Salamone","year":"1998","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.nurt.2008.10.035_bib52","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/ana.1052","article-title":"Prospective study of caffeine consumption and risk of Parkinson's disease in men and women","volume":"50","author":"Ascherio","year":"2001","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nurt.2008.10.035_bib53","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1001\/jama.283.20.2674","article-title":"Association of coffee and caffeine intake with the risk of Parkinson disease","volume":"283","author":"Ross","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.nurt.2008.10.035_bib54","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/mds.21782","article-title":"Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk","volume":"23","author":"Powers","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.nurt.2008.10.035_bib55","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1212\/01.WNL.0000046523.05125.87","article-title":"Caffeine, postmenopausal estrogen, and risk of Parkinson's disease","volume":"60","author":"Ascherio","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.10.035_bib56","doi-asserted-by":"crossref","first-page":"RC143","DOI":"10.1523\/JNEUROSCI.21-10-j0001.2001","article-title":"Neuroprotection by caffeine and A2A adenosine receptor inactivation in a model of Parkinson's disease","volume":"21","author":"Chen","year":"2001","journal-title":"J Neurosci"},{"key":"10.1016\/j.nurt.2008.10.035_bib57","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1046\/j.0022-3042.2001.00694.x","article-title":"Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease","volume":"80","author":"Ikeda","year":"2002","journal-title":"J Neurochem"},{"key":"10.1016\/j.nurt.2008.10.035_bib58","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.parkreldis.2004.06.004","article-title":"Protective effect of caffeine against neurodegeneration in a model of Parkinson's disease in rat: behavioral and histochemical evidence","volume":"10","author":"Joghataie","year":"2004","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.nurt.2008.10.035_bib59","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s00221-005-2302-1","article-title":"Neuroprotection induced by the adenosine A2A antagonist CSC in the 6-OHDA rat model of Parkinsonism: effect on the activity of striatal output pathways","volume":"165","author":"Bov\u00e9","year":"2005","journal-title":"Exp Brain Res"},{"key":"10.1016\/j.nurt.2008.10.035_bib60","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/1098-2396(20010301)39:3<233::AID-SYN1004>3.0.CO;2-K","article-title":"Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats","volume":"39","author":"Pinna","year":"2001","journal-title":"Synapse"},{"key":"10.1016\/j.nurt.2008.10.035_bib61","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1523\/JNEUROSCI.22-03-01054.2002","article-title":"Persistent behavioral sensitization to chronic L-DOPA requires A2A adenosine receptors","volume":"22","author":"Fredduzzi","year":"2002","journal-title":"J Neurosci"},{"key":"10.1016\/j.nurt.2008.10.035_bib62","doi-asserted-by":"crossref","first-page":"13548","DOI":"10.1523\/JNEUROSCI.3554-06.2006","article-title":"Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemi-Parkinsonian mice","volume":"26","author":"Xiao","year":"2006","journal-title":"J Neurosci"},{"key":"10.1016\/j.nurt.2008.10.035_bib63","doi-asserted-by":"crossref","first-page":"3893","DOI":"10.1093\/emboj\/20.15.3893","article-title":"Cell surface monoamine oxidases: enzymes in search of a function","volume":"20","author":"Jalkanen","year":"2001","journal-title":"EMBO J"},{"key":"10.1016\/j.nurt.2008.10.035_bib64","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0161-813X(03)00114-1","article-title":"The FAD binding sites of human monoamine oxidases A and B","volume":"25","author":"Edmondson","year":"2004","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.nurt.2008.10.035_bib65","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/0163-7258(90)90064-9","article-title":"Biochemistry and genetics of monoamine oxidase","volume":"47","author":"Weyler","year":"1990","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.nurt.2008.10.035_bib66","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1146\/annurev.neuro.22.1.197","article-title":"Monoamine oxidase: from genes to behavior","volume":"22","author":"Shih","year":"1999","journal-title":"Annu Rev Neurosci"},{"key":"10.1016\/j.nurt.2008.10.035_bib67","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nrn1883","article-title":"The therapeutic potential of monoamine oxidase inhibitors","volume":"7","author":"Youdim","year":"2006","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.nurt.2008.10.035_bib68","first-page":"55","article-title":"Amine oxidases and their endogenous substrates (with special reference to monoamine oxidase and the brain)","volume":"23","author":"Waldmeier","year":"1987","journal-title":"J Neural Transm Suppl"},{"key":"10.1016\/j.nurt.2008.10.035_bib69","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/S0022-3565(24)35176-6","article-title":"Species-dependent differences in monoamine oxidase A and B-catalyzed oxidation of various C4 substituted 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridinyl derivatives","volume":"291","author":"Inoue","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.nurt.2008.10.035_bib70","doi-asserted-by":"crossref","first-page":"13199","DOI":"10.1016\/S0021-9258(17)38856-7","article-title":"Purification and properties of mitochondrial monoamine oxidase type A from human placenta","volume":"260","author":"Weyler","year":"1985","journal-title":"J Biol Chem"},{"key":"10.1016\/j.nurt.2008.10.035_bib71","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/0024-3205(96)00459-6","article-title":"Localization of monoamine oxidases in human peripheral tissues","volume":"59","author":"Saura","year":"1996","journal-title":"Life Sci"},{"key":"10.1016\/j.nurt.2008.10.035_bib72","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1126\/science.3875898","article-title":"Distinct monoamine oxidase A and B populations in primate brain","volume":"230","author":"Westlund","year":"1985","journal-title":"Science"},{"key":"10.1016\/j.nurt.2008.10.035_bib73","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/brain\/111.6.1441","article-title":"Monoamine oxidases of the human brain and liver","volume":"111","author":"Kalaria","year":"1988","journal-title":"Brain"},{"key":"10.1016\/j.nurt.2008.10.035_bib74","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/0304-3940(88)90794-X","article-title":"Monoamine oxidase activity and distribution in marmoset brain: implications for MPTP toxicity","volume":"90","author":"Willoughby","year":"1988","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.nurt.2008.10.035_bib75","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/0014-4886(92)90055-U","article-title":"Monoamine oxidases of the brains and livers of macaque and cercopithecus monkeys","volume":"115","author":"Riachi","year":"1992","journal-title":"Exp Neurol"},{"key":"10.1016\/j.nurt.2008.10.035_bib76","doi-asserted-by":"crossref","first-page":"6385","DOI":"10.1073\/pnas.79.20.6385","article-title":"Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons","volume":"79","author":"Levitt","year":"1982","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.nurt.2008.10.035_bib77","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1046-2023(02)00083-X","article-title":"Monoamine oxidase: radiotracer development and human studies","volume":"27","author":"Fowler","year":"2002","journal-title":"Methods"},{"key":"10.1016\/j.nurt.2008.10.035_bib78","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/BF01253131","article-title":"The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil","volume":"36","author":"Birkmayer","year":"1975","journal-title":"J Neural Transm"},{"key":"10.1016\/j.nurt.2008.10.035_bib79","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ana.10191","article-title":"Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial","volume":"51","author":"Shoulson","year":"2002","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nurt.2008.10.035_bib80","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1212\/WNL.51.2.520","article-title":"Selegiline delays the onset of disability in de novo parkinsonian patients","volume":"51","author":"P\u00e5lhagen","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.10.035_bib81","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1212\/WNL.67.7_suppl_2.S24","article-title":"Symptom relief in Parkinson disease by safinamide: biochemical and clinical evidence of efficacy beyond MAO-B inhibition","volume":"67","author":"Stocchi","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.10.035_bib82","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/ana.410400116","article-title":"Effect of lazabemide on the progression of disability in early Parkinson's disease","volume":"40","year":"1996","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nurt.2008.10.035_bib83","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1212\/01.wnl.0000204007.46190.54","article-title":"Selegiline slows the progression of the symptoms of Parkinson disease","volume":"66","author":"P\u00e5lhagen","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.10.035_bib84","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/archneur.61.4.561","article-title":"A controlled, randomized, delayed-start study of rasagiline in early Parkinson's disease","volume":"61","year":"2004","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nurt.2008.10.035_bib85","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1600-0773.2001.890501.x","article-title":"Novel aspects of dopamine oxidative metabolism (confounding outcomes take place of certainties)","volume":"89","author":"Gesi","year":"2001","journal-title":"Pharmacol Toxicol"},{"key":"10.1016\/j.nurt.2008.10.035_bib86","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0006-8993(00)02054-0","article-title":"Modulation of dihydroxyphenylacetaldehyde extracellular levels in vivo in the rat striatum after different kinds of pharmacological treatment","volume":"861","author":"Fornai","year":"2000","journal-title":"Brain Res"},{"key":"10.1016\/j.nurt.2008.10.035_bib87","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1124\/pr.59.2.1","article-title":"Neurotoxicity and metabolism of the catecholamine-derived 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde: the role of aldehyde dehydrogenase","volume":"59","author":"Marchitti","year":"2007","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.nurt.2008.10.035_bib88","first-page":"241","article-title":"Oxidative stress: a role in the pathogenesis of Parkinson's disease","volume":"29","author":"G\u00f6tz","year":"1990","journal-title":"J Neural Transm Suppl"},{"key":"10.1016\/j.nurt.2008.10.035_bib89","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1471-4159.1989.tb09150.x","article-title":"Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains","volume":"52","author":"Riederer","year":"1989","journal-title":"J Neurochem"},{"key":"10.1016\/j.nurt.2008.10.035_bib90","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s00702-004-0212-1","article-title":"Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion\/cellular matrix and vesicle trafficking genes","volume":"111","author":"Gr\u00fcnblatt","year":"2004","journal-title":"J Neural Transm"},{"key":"10.1016\/j.nurt.2008.10.035_bib91","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/0006-291X(84)91293-2","article-title":"Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase","volume":"120","author":"Chiba","year":"1984","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.nurt.2008.10.035_bib92","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1126\/science.6610213","article-title":"Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice","volume":"224","author":"Heikkila","year":"1984","journal-title":"Science"},{"key":"10.1016\/j.nurt.2008.10.035_bib93","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1126\/science.6823561","article-title":"Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis","volume":"219","author":"Langston","year":"1983","journal-title":"Science"},{"key":"10.1016\/j.nurt.2008.10.035_bib94","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/311467a0","article-title":"Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors","volume":"311","author":"Heikkila","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.nurt.2008.10.035_bib95","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0892-0362(02)00210-6","article-title":"Potential neurotoxic \u201cagents provocateurs\u201d in Parkinson's disease","volume":"24","author":"Collins","year":"2002","journal-title":"Neurotoxicol Teratol"},{"key":"10.1016\/j.nurt.2008.10.035_bib96","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.brainresrev.2004.12.027","article-title":"Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives","author":"Mandel","year":"2005","journal-title":"Brain Res Brain Res Rev"},{"key":"10.1016\/j.nurt.2008.10.035_bib97","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1358\/dot.2005.41.6.893613","article-title":"Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline","volume":"41","author":"Youdim","year":"2005","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.nurt.2008.10.035_bib98","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0892-0362(02)00221-0","article-title":"Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes","volume":"24","author":"Maruyama","year":"2002","journal-title":"Neurotoxicol Teratol"},{"key":"10.1016\/j.nurt.2008.10.035_bib99","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0024-3205(00)00643-3","article-title":"Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat","volume":"67","author":"Carrillo","year":"2000","journal-title":"Life Sci"},{"key":"10.1016\/j.nurt.2008.10.035_bib100","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0047-6374(99)00065-2","article-title":"Pharmacological modifications of endogenous antioxidant enzymes with special reference to the effects of deprenyl: a possible antioxidant strategy","volume":"111","author":"Kitani","year":"1999","journal-title":"Mech Ageing Dev"},{"key":"10.1016\/j.nurt.2008.10.035_bib101","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0031-6997(24)01396-6","article-title":"Actions of caffeine in the brain with special reference to factors that contribute to its widespread use","volume":"51","author":"Fredholm","year":"1999","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.nurt.2008.10.035_bib102","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0223-5234(03)00042-4","article-title":"Recent developments in the field of A2A and A3 adenosine receptor antagonists","volume":"38","author":"Baraldi","year":"2003","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.nurt.2008.10.035_bib103","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0014-827X(01)01024-2","article-title":"Selective adenosine A2A receptor antagonists","volume":"56","author":"Ongini","year":"2001","journal-title":"Farmaco"},{"key":"10.1016\/j.nurt.2008.10.035_bib104","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s002130051146","article-title":"Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP","volume":"147","author":"Shiozaki","year":"1999","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.nurt.2008.10.035_bib105","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1021\/jm00069a009","article-title":"Adenosine A1 antagonists","volume":"36","author":"Suzuki","year":"1993","journal-title":"J Med Chem"},{"key":"10.1016\/j.nurt.2008.10.035_bib106","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0014-2999(94)90551-7","article-title":"KF 17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity","volume":"256","author":"Kanda","year":"1994","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.nurt.2008.10.035_bib107","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0223-5234(96)80007-9","article-title":"(E)-1-(Heterocyclyl or cyclohexyl)-2-[1,3,7-trisubstituted(xanthin-8-yl)]ethenes as A2A adenosine receptor antagonists","volume":"31","author":"Del Giudice","year":"1996","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.nurt.2008.10.035_bib108","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1016\/j.bmc.2007.03.046","article-title":"Inhibition of monoamine oxidase B by selected benzimidazole and caffeine analogues","volume":"15","author":"Van den Berg","year":"2007","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.nurt.2008.10.035_bib109","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1212\/01.WNL.0000095215.97585.59","article-title":"Monoamine oxidase B inhibition and neuroprotection: studies on selective adenosine A2A receptor antagonists","volume":"61","author":"Castagnoli","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.10.035_bib110","doi-asserted-by":"crossref","first-page":"8676","DOI":"10.1016\/j.bmc.2008.07.088","article-title":"Dual inhibition of monoamine oxidase B and antagonism of the adenosine A2A receptor by (E,E)-8-(4-phenylbutadien-1-yl)caffeine analogues","volume":"16","author":"Pretorius","year":"2008","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.nurt.2008.10.035_bib111","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nsb732","article-title":"Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders","volume":"9","author":"Binda","year":"2002","journal-title":"Nat Struct Biol"},{"key":"10.1016\/j.nurt.2008.10.035_bib112","doi-asserted-by":"crossref","first-page":"9750","DOI":"10.1073\/pnas.1633804100","article-title":"Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures","volume":"100","author":"Binda","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.nurt.2008.10.035_bib113","doi-asserted-by":"crossref","first-page":"15761","DOI":"10.1074\/jbc.M500949200","article-title":"Demonstration of isoleucine 199 as a structural determinant for the selective inhibition of human monoamine oxidase B by specific reversible inhibitors","volume":"280","author":"Hub\u00e1lek","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.nurt.2008.10.035_bib114","doi-asserted-by":"crossref","first-page":"5848","DOI":"10.1021\/jm070677y","article-title":"Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs","volume":"50","author":"Binda","year":"2007","journal-title":"J Med Chem"},{"key":"10.1016\/j.nurt.2008.10.035_bib115","doi-asserted-by":"crossref","first-page":"6446","DOI":"10.1021\/jm701225u","article-title":"Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease","volume":"50","author":"Bolognesi","year":"2007","journal-title":"J Med Chem"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923004403?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923004403?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1016\/j.nurt.2008.10.035","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:37:55Z","timestamp":1761806275000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923004403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":115,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["S1878747923004403"],"URL":"https:\/\/doi.org\/10.1016\/j.nurt.2008.10.035","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2009,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual-Target\u2013Directed Drugs that Block Monoamine Oxidase B and Adenosine A2A Receptors for Parkinson's Disease","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nurt.2008.10.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}